Humacyte financials
$0.5327−2.65%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $406.0K | $495.0K | $467.0K | $753.0K | $301.0K | $517.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$825.0K | -$1.5M | -$8.6M | $493.0K | $88.0K | $370.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | −203.2% | −311.7% | −1844.8% | 65.5% | 29.2% | 71.6% | — | — | — | — | — | — |
| Operating income | -$29.7M | -$28.9M | -$30.8M | -$24.4M | -$35.2M | -$23.2M | -$28.1M | -$30.2M | -$29.5M | -$31.2M | -$14.5M | -$25.8M |
| Net income | -$36.8M | -$17.6M | -$24.8M | -$17.5M | -$37.7M | $39.1M | -$20.9M | -$39.2M | -$56.7M | -$31.9M | -$25.1M | -$26.0M |
| Net margin | −9064.5% | −3559.4% | −5311.3% | −2325.4% | −12511.0% | 7570.4% | — | — | — | — | — | — |
| Diluted EPS | $-0.16 | $-0.09 | $-0.13 | $-0.11 | $-0.24 | $0.28 | $-0.16 | $-0.33 | $-0.48 | $-0.29 | $-0.24 | $-0.25 |
| EBITDA | -$28.4M | -$27.6M | -$31.1M | -$21.5M | -$33.9M | -$21.9M | -$28.4M | -$27.4M | -$28.8M | -$24.8M | -$24.3M | -$22.8M |
| Operating cash flow | -$22.1M | -$25.1M | -$26.1M | -$23.9M | -$26.4M | -$28.6M | -$26.6M | -$22.9M | -$21.3M | -$27.3M | -$17.4M | -$24.7M |
| Free cash flow | -$22.2M | -$25.3M | -$26.2M | -$24.0M | -$27.0M | -$28.8M | -$26.6M | -$23.8M | -$21.5M | -$27.7M | -$17.5M | -$25.2M |
| Diluted shares | 234.2M | 197.8M | 187.1M | 158.3M | 155.4M | 131.8M | 127.1M | 119.4M | 119.2M | 108.2M | 103.6M | 103.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.9M | $48.5M | $50.5M | $19.5M | $38.0M | $62.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $66.2M | $65.9M | $64.8M | $50.6M | $83.7M | $82.2M |
| Total assets | $138.1M | $110.6M | $116.4M | $91.5M | $138.8M | $162.6M |
| Total liabilities | $106.8M | $98.9M | $113.3M | $96.3M | $134.7M | $126.5M |
| Shareholders' equity | $31.3M | $11.6M | $3.1M | -$4.8M | $4.1M | $36.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology